Podcasts about pharmacological

GLP-1 receptor agonists have changed the landscape of obesity treatment, offering levels of weight loss once thought unattainable without surgery. But what happens after the weight is lost? And can we really talk about success without talking about maintenance? While much of the public discourse fixates on dramatic weight loss numbers, the harder question is what comes next. Can lifestyle interventions alone sustain weight loss after GLP-1 cessation? How do metabolic adaptations and behavioral relapse factor in? And what does the data actually show about relapse rates, nutritional adequacy, and lean mass preservation when using these medications? In this episode, Danny sits down with Tara Schmidt, dietitian at the Mayo Clinic, to examine the intersection of pharmacology and behavior in long-term weight management. Tara Schmidt is a registered dietitian and an instructor of nutrition at Mayo Clinic. As the lead dietitian for the Mayo Clinic Diet, she provides guidance rooted in evidence-based principles. She hosts the Mayo Clinic On Nutrition podcast and co-authored The Mayo Clinic Diet: Weight Loss Medications Edition. Timestamps [05:17] Understanding weight loss maintenance [08:44] Defining success in weight loss maintenance [11:54] Predictors of maintenance: self-monitoring and behavioral strategies [23:37] Pharmacological interventions: GLP-1 receptor agonists [31:06] Dietary considerations for those taking GLP-1 RAs [37:07] Addressing misconceptions about weight loss drugs [42:48] Final thoughts and takeaways [48:49] Key ideas (Premium-only) Links/Resources Subscribe to Sigma Nutrition Premium Go to episode page Join the Sigma email newsletter for free Enroll in the next cohort of our Applied Nutrition Literacy course Visit sigmanutrition.com

Did you know that Obsessive-Compulsive Disorder (OCD) affects approximately 1 in 200 children, with symptoms often emerging between the ages of 7 and 12? As pediatricians, you're likely the first to encounter these patients, making early recognition and intervention critical for achieving optimal outcomes. In this episode, we'll provide you with the knowledge and tools needed to accurately diagnose and effectively manage OCD, laying the foundation for better long-term care. Dr. Theresa Fiagbe, a second-year Child Psychiatry Fellow, Dr. Dale Peeples, Associate Professor of Child Psychiatry, and Alisha Patel, Medical Student at the Medical College of Georgia, join forces to unpack the complexities of OCD in children and adolescents. Tune in as we: Explore key diagnostic criteria and the most effective screening tools for identifying OCD in pediatric patients Discuss evidence-based treatments such as Cognitive Behavioral Therapy (CBT) and SSRIs, and how to incorporate them into your practice Review common comorbid conditions, like anxiety and PANDAS, that can complicate diagnosis and treatment Examine the impact of OCD on school performance, social interactions, and family life Share practical guidance on managing long-term care to prevent relapse and ensure successful outcomes Whether you're encountering OCD symptoms in a patient for the first time or seeking to enhance your expertise, this episode will equip you with the essential tools to improve diagnosis and treatment. Special thanks to Dr. Yang for editing and Dr. Sarah Straka, and Dr. Baris Olten for peer reviewing this episode. CME Credit Available: Link Coming Soon! References: American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing. Berman, L., & Flessner, C. A. (2014). Pediatric obsessive-compulsive disorder: Diagnostic and treatment issues. Journal of the American Academy of Child and Adolescent Psychiatry, 53(2), 123-131. https://doi.org/10.1016/j.jaac.2013.10.003 Clark, C. A., & Scharf, R. (2020). Cognitive-behavioral therapy for obsessive-compulsive disorder in children and adolescents: Current trends and future directions. Journal of the American Academy of Child and Adolescent Psychiatry, 59(9), 971-979. https://doi.org/10.1016/j.jaac.2020.05.007 Fahrion, S., & Goodwin, G. M. (2019). Pharmacological treatment of pediatric obsessive-compulsive disorder: SSRIs, clomipramine, and beyond. Current Psychiatry Reports, 21(8), 58-66. https://doi.org/10.1007/s11920-019-1040-3 Franklin, M. E., & March, J. S. (2015). Treatment of obsessive-compulsive disorder in children and adolescents. Pediatric Clinics of North America, 62(3), 529-545. https://doi.org/10.1016/j.pcl.2015.02.004 March, J. S., & Mulle, K. (2017). OCD in children and adolescents: A review of treatments and practical guidance. The Psychiatric Clinics of North America, 40(2), 199-208. https://doi.org/10.1016/j.psc.2017.01.002 Murphy, T. K., & Pincus, D. B. (2019). Pediatric obsessive-compulsive disorder: Diagnosis, treatment, and future directions. Current Opinion in Pediatrics, 31(4), 517-524. https://doi.org/10.1097/MOP.0000000000000801 PANDA Study Group. (2017). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). Journal of the American Academy of Child and Adolescent Psychiatry, 56(11), 933-940. https://doi.org/10.1016/j.jaac.2017.07.866 Peris, T. S., & Piacentini, J. (2021). Pediatric obsessive-compulsive disorder: Treatment strategies and challenges. Journal of Clinical Child and Adolescent Psychology, 50(1), 32-43. https://doi.org/10.1080/15374416.2020.1831504 Reaven, J. (2018). Screening for pediatric obsessive-compulsive disorder: Tools, guidelines, and challenges. Child and Adolescent Mental Health, 23(3), 133-139. https://doi.org/10.1111/camh.12267 Thienemann, M., & McGuire, L. (2019). Treating pediatric OCD with a focus on cognitive-behavioral therapy: Evidence and efficacy. Journal of Clinical Child and Adolescent Psychology, 48(4), 530-538. https://doi.org/10.1080/15374416.2019.1612851

BUFFALO, NY — May 13, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 4, on April 7, 2025, titled “Pharmacological recapitulation of the lean phenotype induced by the lifespan-extending sulfur amino acid-restricted diet.” In this study, the research team, led by first author Naidu B. Ommi and corresponding author Sailendra N. Nichenametla from the Orentreich Foundation for the Advancement of Science Inc., investigated whether the drug buthionine sulfoximine (BSO) could replicate the effects of sulfur amino acid restriction (SAAR), a challenging diet known to reduce obesity. The study found that BSO produced similar reductions in fat mass and weight gain. This drug-based approach may offer a simpler and safer treatment for obesity, especially for those unable to follow strict dietary plans. Obesity and metabolic disorders raise the risk of chronic illnesses like heart disease, diabetes, and Alzheimer's disease. While SAAR, a diet low in the amino-acids methionine and cysteine, has shown powerful health benefits in animal studies, its translation to humans has been limited by adherence challenges. This new study explored whether BSO, a compound that lowers glutathione (GSH) levels in the body, could mimic SAAR's effects without dietary restriction. Researchers tested four groups of obese mice on high-fat diets. One group received the SAAR diet, another was given a regular diet plus BSO, while two control groups received either no treatment or a supplement that increased GSH levels. The BSO-treated mice showed lower fat mass, reduced liver fat, and prevented weight gain, results comparable to those on the SAAR diet. These benefits occurred without reducing food intake or muscle mass, making BSO a particularly promising treatment option. “BSO mice exhibited all SAAR-induced changes, with two notable differences, i.e., a smaller effect size than that of the SAAR diet and a higher predilection for molecular changes in kidneys than in the liver.” Additional findings revealed that both the SAAR diet and BSO influenced metabolic activity by activating pathways related to fat storage, but they did so in different organs. The SAAR diet had stronger effects in the liver, while BSO acted more in the kidneys. Both interventions increased levels of the amino acid serine, which is associated with lower fat production. Unlike many obesity treatments that suppress appetite or reduce muscle, BSO helped prevent fat accumulation while preserving lean mass and food consumption. No signs of liver or kidney toxicity were observed during the 13-week study, suggesting the drug's safety at the tested dose. Since BSO has previously been evaluated in human clinical trials for other conditions, repurposing it for metabolic diseases may be relatively straightforward. However, the researchers point out that there should be further studies in both animals and humans. If successful, this strategy could provide a practical alternative to difficult-to-maintain diets and help more people manage weight long-term. DOI: https://doi.org/10.18632/aging.206237 Corresponding author: Sailendra N. Nichenametla – snichenametla@orentreich.org Video short - https://www.youtube.com/watch?v=AcCzYTIElGY Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords: aging, buthionine sulfoximine, thiols, serine, anti-obesity drugs To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Drs. Lebin and Nagle-Yang discuss the pharmacological management of PPD, with a focus on the risks and benefits of selective serotonin reuptake inhibitors (SSRIs) and zuranolone.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this quarterly podcast summary (QPS) episode, Peter summarizes his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from his discussions on diverse topics such as aerobic efficiency and VO2 max with Olav Aleksander Bu; insulin resistance with Ralph DeFronzo; economics of the US healthcare system and cost-saving strategies with Saum Sutaria; diagnosis and treatment of autism, ADHD, and anxiety in children with Trenna Sutcliffe; and strength training with Mike Israetel. Additionally, Peter shares any personal behavioral adjustments or modifications to his patient care practices that have arisen from these fascinating discussions. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #338 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Overview of topics to be discussed [2:00]; Olav Aleksander Bu Pt.2 episode: metrics to track aerobic efficiency and insights about VO2 max, and the ability of increased carbohydrate consumption to boost performance [4:30]; The best practices for performing a VO2 max test, the differences between VO2 max training and all-out efforts, and the role of energy intake in endurance performance [14:45]; Ralph DeFronzo episode: the pathophysiology of insulin resistance and type 2 diabetes—how they impact different organs, flaws in conventional diabetes treatment, and more [24:30]; Understanding type 2 diabetes beyond the traditional triumvirate of features: the “ominous octet” describes changes in other organs [31:45]; Pharmacological treatments for insulin resistance and type 2 diabetes [41:30]; The importance of early detection and intervention in insulin resistance [50:30]; Saum Sutaria episode: the economic and systemic drivers of high healthcare costs in the U.S. [54:00]; Reducing health care costs: redefining health insurance, lowering drug prices while maintaining innovation, leveraging AI for efficiency, and more [1:07:15]; Trenna Sutcliffe episode: insights on autism, ADHD, and anxiety in children—definitions and diagnosis [1:11:45]; Exploring the rising prevalence of autism spectrum disorder [1:17:15]; Trenna's views on caring for children with autism [1:21:15]; Misconceptions around vaccines and autism [1:26:00]; Mike Israetel episode: insights about strength training, minimum effective dose, troubleshooting plateaus, tips for beginners, and more [1:28:15]; Topics Peter is interested in exploring in future podcasts [1:40:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

  On this episode of Unsupervised Learning Razib talks to Nathan Lents about his new book, The Sexual Evolution: A Provocative Look at Sexual Behavior Through the Lens of Evolution. A professor at John Jay College in New York City, Lents earned a Ph.D. in Pharmacological and Physiological Sciences in 2004 at Saint Louis University School of Medicine, and did his postdoctoral fellowship in cancer genomics at NYU Medical Center. Lents' research ranges from the evolution of molecular mechanisms to behavioral ecology. He is also the author of Not So Different: Finding Human Nature in Animals and Human Errors: A Panorama of Our Glitches, from Pointless Bones to Broken Genes.   Lents reached out to Razib after hearing his podcast with Conn Carroll, about his book Sex and the Citizen: How the Assault on Marriage Is Destroying Democracy. Lents felt that Carroll overemphasized the role of monogamy during humanity's long forager phase, and more precisely, failed to distinguish social monogamy and genetic monogamy. As noted in The Sexual Evolution, many socially monogamous species, like most birds, engage in enough extra-pair copulation so that genetic fidelity is considerably lower than 100%. Razib and Lents then go back to first principles, talking about the origins of sex, and its persistence in the face of the two-fold cost of reproduction in dimorphous organisms. They discuss why specialized males and females exist in complex organisms as distinct as flowering plants and humans. Lents also discusses the reviews empirical literature on homosexual behavior, variation in sex differences across many classes of organisms and the application of evolutionary thinking to our understanding of the human past. Then they discuss the relevance of evolutionary biology for understanding the human present, and our current debates about marriage, sex and gender. Finally, they consider the differences between sex and gender, and the idea that both can be conceptualized in a nonbinary fashion.

In this episode, hosts Drs. Peter Lu and Jason Silverman talk to Dr. Rima Fawaz about the role of GLP-1 receptor agonists in the treatment of children and adolescents with metabolic dysfunction-associated steatotic liver disease or MASLD (the artist formerly known as non-alcoholic fatty liver disease or NAFLD). We discuss what these medications do, what we know about their positive and negative effects, and how we should be using them based on the current literature. Dr. Fawaz is Medical Director of Pediatric Hepatology and Liver Transplantation at Yale New Haven Children's Hospital and Associate Professor at Yale School of Medicine.Learning Objectives:Understand the therapeutic and potential adverse effects of GLP-1 receptor agonists.Recognize that the foundation of obesity and MASLD treatment remains lifestyle changes focused on diet and exercise.Recognize the role that GLP-1 receptor agonists will play in our care for children and adolescents with obesity and MASLD.Links:Abou Jaoudeh RAR, et al. Pharmacological management of pediatric metabolic dysfunction-associated liver disaese. J Pediatr Gastroenterol Nutr. 2025.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Un nouvel épisode du Pharmascope est disponible! Pour ce 150e épisode, Nicolas, Isabelle et Olivier, inspirés par une nouvelle série documentaire, discutent d'andropause. Cette première partie est consacrée à tenter de démystifier l'andropause et à comparer les différentes formulations de testostérone. Les objectifs pour cet épisode sont les suivants: Discuter de l'épidémiologie et de l'étiologie de l'andropause Expliquer la présentation clinique et l'évaluation de l'andropause Comparer les avantages et désavantages de chaque formulation de testostérone dans le but de procéder à une décision partagée sur le choix d'une formulation de testostérone Ressources pertinentes en lien avec l'épisode  Série documentaire « L'andropause sans tabou ». Disponible sur l'EXTRA d'ICI TOU.TV Salonia A et coll. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019 May 30;5(1):38. Lajeunesse-Viens G. Andropause : Vérités et conséquences. Médecin du Québec, mai 2020, 35-39. (réservé aux abonnés) Dugré N, Fillion M. Docteur, j'ai besoin de testostérone! Médecin du Québec, mai 2020, 29-33. (réservé aux abonnés) Morales A et coll; Canadian Men's Health Foundation Multidisciplinary Guidelines Task Force on Testosterone Deficiency. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ. 2015 Dec 8;187(18):1369-1377. Rastrelli G, Maggi M, Corona G. Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol. 2018 Apr;11(4):439-458.

In this episode Dr. Ludy Shih briefly describes the current approach to tremor, including pharmacological treatments, botulinum toxin injections and deep brain stimulation. She further dives into the exciting new developments of the past few years and new drugs coming down the pipeline.

In this episode of our special pediatric psychopharmacology series, Dr. Jeffrey Strawn and Dr. Robyn Thom discuss the situations in which psychotropic medications are appropriate for children with autism spectrum disorder. They also explore strategies for managing side effects of these medications, including cases involving polypharmacy in this population.   Jeffrey R. Strawn, MD is a Professor and Associate Vice Chair of Research in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati (UC) College of Medicine, the Assistant Director of Clinical and Translational Research in the Center for Clinical & Translational Science and Training at UC, and an Associate Professor in the Department of Pediatrics at UC and Cincinnati Children's Hospital Medical Center.  Robyn Thom, MD is an Assistant Professor at Harvard Medical School and a staff psychiatrist at the Massachusetts General Hospital Lurie Center for Autism. Dr. Thom specializes in treating children and adults with autism spectrum disorder and other neurodevelopmental disorders, anxiety disorders, and mood disorders.  Save $100 on registration for 2025 NEI Spring Congress with code NEIPOD25 Register today at https://nei.global/spcongress25p Never miss an episode!

In today's episode Nic chats to one of our all time favourite deep dive guests, Dr Martin Khoury, as we shift our focus to understanding pharmacology and how it relates to managing running related pain. We'll explore everything from the efficacy of analgesics and the placebo effect to the challenges and ethics of chronic pain management. Whether you're curious about why a simple painkiller could pose risks or how to handle discomfort during a run, Martin provides key insights into making informed decisions. Plus, we'll touch on the risks of over-the-counter meds and the surprising effectiveness of non-invasive approaches like good nutrition and adequate sleep. As athletes and enthusiasts, it's crucial we understand the balance between natural discomfort and the kind of pain that signals deeper issues. Join us in navigating this intricate landscape, and learn how to enhance your running performance without compromising your health. We hope you enjoy today's conversation and feel free to pop us any questions you may have.

In this special Complex Care Journal Club podcast episode, co-hosts Drs. Kilby Mann and Kristie Malik interview presenters of posters and oral abstracts relevant to the care of children with medical complexity at the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) 78th Annual Meeting in Quebec City, Canada that took place October 23rd-26th 2024. Speakers describe the implications of their study findings, messages for patients and families, and priority areas for research that they hope can be investigated further by the complex care community in the coming years. SPEAKERS Tori Bahr, MD MedPeds Complex Care Physician Section Chief of Pediatrics Gillette Children's, St. Paul, Minnesota Laura Brunton, PT, PhD Associate Professor School of Physical Therapy Western University, London, Ontario Caitlin Cassidy, MD Associate Professor Departments of Physical Medicine & Rehabilitation and Pediatrics Western University, London, Ontario Adam Rosenbloom, MD, MPH Complex Care Pediatrician Dell Children's Medical Center University of Texas at Austin, Dell Medical School Cristina Sarmiento, MD Assistant Professor Department of Physical Medicine and Rehabilitation University of Colorado Anschutz Medical Campus, Aurora, Colorado Julie Stutzbach, PT, DPT, PhD Assistant Professor School of Rehabilitative and Health Sciences Regis University, Denver, Colorado HOSTS Kristina Malik, MD Assistant Professor of Pediatrics, University of Colorado School of Medicine Medical Director, KidStreet Pediatrician, Special Care Clinic, Children's Hospital Colorado Kilby Mann, MD Assistant Professor Pediatric Rehabilitation Medicine Children's Hospital Colorado DATE Initial publication date: November 11, 2024. ARTICLES AND ADDITIONAL REFERENCES • American Academy for Cerebral Palsy and Developmental Medicine (AACPDM), https://www.aacpdm.org/ • AACPDM Complex Care Committee (https://www.aacpdm.org/about-us/committees/complex-care) • Houtrow AJ, Hurwitz MB. A dearth of disability-related competencies in Accreditation Council for Graduate Medical Education's Milestones 2.0. PM R. 2024 Aug 23. doi: 10.1002/pmrj.13257. Epub ahead of print. PMID: 39177053. • Fehlings D, Agnew B, Gimeno H, Harvey A, Himmelmann K, Lin JP, Mink JW, Monbaliu E, Rice J, Bohn E, Falck-Ytter Y. Pharmacological and neurosurgical management of cerebral palsy and dystonia: Clinical practice guideline update. Dev Med Child Neurol. 2024 Sep;66(9):1133-1147. doi: 10.1111/dmcn.15921. Epub 2024 Apr 19. PMID: 38640091. • AACPDM Care Pathway Dystonia in Cerebral Palsy, https://www.aacpdm.org/publications/care-pathways/dystonia-in-cerebral-palsy TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/p9pj6g7sxn5kjmmgps5wnk4/111124_-_Complex_Care_at_the_American_Academy_for_Cerebral_Palsy_and_Developmental_Medicine_Annual_Meeting Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access-and thus at no expense to the user.For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Malik K, Bahr T, Brunton L, Cassidy C, Rosenbloom A, Sarmiento C, Stuzbach J, Mann K. Complex Care at the American Academy for Cerebral Palsy and Developmental Medicine Annual Meeting. 11/2024. OPENPediatrics. Online Podcast.. https://soundcloud.com/openpediatrics/complex-care-at-the-aacpdm-2024.

Another psychotic episode of pharmacological torture from The Anointing The Sick Show, hosted by Halo Of The Goat Radio. It will soon be the 'Best Of' season with many Blogs etc publishing their top albums for 2024. I'll be doing the same myself but first I'm highlighting some of my last years Dirty Dozen which was represented  by the Doom Charts including bands such as Ceased Sunfire, Divinist, Adversvm, Cannabus, Dread Witch and Spawn Of Evil, just incase anyone missed these fine albums.~ Embrace The Sickness ~Into The DeepSvdestadaVorvanCeased SunfireDivinistAdversvmCannabusDread WitchSpawn Of EvilArchitecture of AggressionBloodbeastNethervaultBoccSonic MoonDoomsday DementiaDragonbreed

Laura Beaton chats with endocrinologist Jillian Tay about her article on the pharmacological management of polycystic ovary syndrome (PCOS). They discuss the 2023 international PCOS guideline, including updates to the diagnostic criteria, and different pharmacological treatments to manage symptoms of PCOS. Read the full article by Jillian and her co-author, Carolyn Ee, in Australian Prescriber.

Yep, it's time for another romp through pop culture and (trigger warning) politics as the men of GLoP riff on college campus antics (one of the panelists is in college at the moment), possible election unrest, Game of Thrones v. Monty Python and The Holy Grail, the problem with liking Hitler's generals, the greatest Faye Dunaway story you have ever heard, ABC's Dr. Odyssey, who would win a Harris against Trump IQ test, and Rob makes a very mainstream recommendation.

Yep, it’s time for another romp through pop culture and (trigger warning) politics as the men of GLoP riff on college campus antics (one of the panelists is in college at the moment), possible election unrest, Game of Thrones v. Monty Python and The Holy Grail, the problem with liking Hitler’s generals, the greatest Faye Dunaway […]

Nate Johnson, PharmD, BCPS discusses updates in the pharmacologic treatment for psoriasis.   For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE

Welcome to a mini podcast series where we take a deep dive on an herb. We hope to better aquaint you with the day's herb while we cover everything from the mystic to the science, the habitat to constiuents. Amy takes you on a journey to know our first Materia Medica Monday plant, Hawthorn. Hawthorn is known as heart food! Today we explore:-Actions-How to prepare it-Where to find it-The science behind why it's so usefulIf you enjoyed this podcast please leave a review or follow us on instagram @herbgirlsathensShow Notes:The Herb Girls Hawthorn Materia Medica (free)Materia Medica Resources:The Modern Herbal Dispensary - Thomas EasleyWinston & Kuhn's Herbal Therapy & Supplements - Merrily A. Khun & David Winston (Amy's favorite resource mentioned in the podcast)The Herbal Academy: Herbarium (online subscription ~$6.50 a month)Materia Medica Monthly: Sajah Popham - also subscription but very indepthAmerican Botanical CouncilStudies:Gildor A. (1998). Crataegus oxycantha and heart failure. Circulation. 98(19):2098.Loew D. (1994). Pharmacological and clinical results with Crataegus special extracts in cardiac insufficiency. ESCOP Phytotelegram. 6:20-26Tassell MC, Kingston R, Gilroy D, Lehane M, Furey A. Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease. Pharmacogn Rev. 2010 Jan;4(7):32-41.Zapfe jun G. Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine. 2001 Jul;8(4):262-6.

Some Cochrane Reviews include network meta-analyses to bring together a range of comparisons to help identify the relative effects of different interventions and to rank them based on effectiveness. In June 2024, we published one of these, examining cardioversion for atrial arrhythmias. In this podcast, one of the authors Rui Providencia (left) interviews the first author, Kishore Kukendra‐Rajah (right) both from Barts Health NHS Trust in London in the UK.

Some Cochrane Reviews include network meta-analyses to bring together a range of comparisons to help identify the relative effects of different interventions and to rank them based on effectiveness. In June 2024, we published one of these, examining cardioversion for atrial arrhythmias. In this podcast, one of the authors Rui Providencia (left) interviews the first author, Kishore Kukendra‐Rajah (right) both from Barts Health NHS Trust in London in the UK.

In this episode, we explore the use of benzodiazepines and nonbenzodiazepine hypnotics for managing insomnia in major depressive disorder. How do these medications work, and what are the key considerations when prescribing them? Join us as we navigate the complexities of pharmacologic interventions for insomnia. Faculty: Amit Chopra, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Navigating Insomnia in Major Depressive Disorder: Advances in Management Pharmacologic Interventions for Insomnia: Benzodiazepines and Non-Benzodiazepine Hypnotics

00:00:00 - Surf's Up: Season 5 Episode 21 One important session at the EASL Congress 2024 involved the presentation of the new MASLD Clinical Practice Guidelines. CPG co-authors Elisabetta Bugianesi and Frank Tacke join Louise Campbell and Roger Green to share their perspectives on the guidelines' development some key recommendations.  00:09:36 - Revising the guidelines Roger asks the co-authors to describe the process that led to the 2021 decision to revise the guidelines. EASL was the initial driver; EASD and EASO joined the process. They formed a committee of 15 leaders and assembled a Delphi panel of 46 individuals from different stakeholder communities.  Elisabetta describes the "big advantage" of this collaboration: it conveyed the need for a common way to manage co-morbid patients with MASLD. To Frank, this approach strengthened the guidelines by putting the liver in the center of metabolic disease. Louise asks whether the guidelines will increase the profile of liver disease in other specialties. Elisabetta says "it takes time" but says that the nature of cirrhosis and HCC might make this easier.00:19:07 - Adding resmetirom before approvalEarlier, Louise praised the inclusion of resmetirom in the guidelines, Frank notes that this section was added to the guidelines within a month before their release and praises the "very engaged Delphi panel" that reacted and voted quickly.  He proceeds to discuss how the Delphi panel was formed.00:23:24 - Major issues in screening, diagnosing and case-managing patientsElisabetta starts by saying that resmetirom's approval created momentum for screening. She says the approach identifies patients before cirrhosis or HCC in pre-cirrhotic patients. Frank points out "a major breakthrough": these guidelines do not rely on biopsy.  00:28:04 - Non-medical factors Louise lauds the document's the broad range of diets that will make the document valuable around the world . Frank adds that the guidelines have adjusted thresholds  adapted to the ethnic and socioeconomic background of the individual. 00:30:52 - Pharmacological issues in the new CPG Frank starts the pharmacological discussion noting that the CPG drives holistic thinking about the liver in a metabolic context. Elisabetta notes that while no drugs are efficacious for cirrhosis, the document does report that some drugs are safe for these patients, although sometimes with adjusted doses. 00:33:39 - Screening for cirrhosisFrank concurs that the document provides guidance on managing patients with end-stage liver disease and also discusses how to manage cirrhosis and its various complications. Elisabetta says that HCC can be hard to find in a fatty liver. 00:36:36 - Cardiometabolic nursing as a future training and specialtyLouise suggests that these guidelines "pinpoint...a role of the potential future" for nurses who can support the entire cardiometabolic syndrome. This document might drive a curriculum for such a specialization.00:38:48 - What adjustments would you like to see in the healthcare system?The last set of questions begins with Roger asking what kinds of changes the authors would like to see in the healthcare system.  The discussion revolves around a "cardiometabolic" perspective but in terms of nurse training and the care provided in a hepatologist's office. 00:43:18 - Winding downAs the conversation winds down, each panelist offers a final comment or question.00:47:59 - Question of the WeekRoger asks how readily listeners believe the guidelines will be implemented, and which sections will be easiest and hardest to implement. 00:48:32 - Business ReportThe next EASL Congress review episodes, starting office hours, and a vault discussion from 2023's clinical care pathway document. 

Y'all thought we'd stay away this long??? We're baaaccckkk! And this is #2 of the TWO bonus episodes we produced for Season 8! In this episode we tackle the different types of research with Dr. Irwin and Dr. Massimo, the Co-Directors of the Penn FTD Center. Some of the questions we ask: -What are the different types of research? Pharmacological vs. not? -How does brain donation support research? -How do we make research more accessible? Research and clinical trials are such an important aspect of our advocacy and we are thrilled to bring you these 2 episodes stacked full of useful info! Check out the companion blog post for this episode which can be read ⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠ full of more resources and info. Special thank you to The AFTD for their collaboration and support of these blogs! -- We want to send big love to the entire ⁠⁠⁠⁠⁠Penn FTD Center Team⁠⁠⁠⁠⁠. To sign up for our e-mail visit our website ⁠⁠⁠⁠⁠remembermeftd.com⁠⁠⁠⁠⁠. Remember Me is proud to work with ⁠⁠⁠⁠⁠⁠⁠LearnFTD⁠⁠⁠⁠⁠⁠⁠, by Alector in working to raise awareness of FTD.. For additional information and resources, visit ⁠⁠⁠⁠⁠⁠⁠LearnFTD.com ⁠⁠⁠⁠⁠⁠⁠Thank you for supporting our work and for supporting the FTD community.  --- Support this podcast: https://podcasters.spotify.com/pod/show/rememberme/support

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter provides insights on a broad range of important topics. He delves into the prevention of cognitive decline, the link between cardiovascular disease and Alzheimer's disease, and methods to lower blood glucose, insulin, and apoB. He also addresses nutrition-related queries, exploring the impact of dietary habits on weight loss and longevity, how a person can identify the best diet for themselves, and common nutrition myths. Additional discussions include optimal blood pressure, daily step goals, the benefits of standing versus sitting desks, and much more. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #60 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Overview of topics and episode format [1:40]; Preventing cognitive decline [5:00]; How to lower blood glucose and insulin [13:30]; The relationship between lipids, CVD, and Alzheimer's disease, and whether statins can increase the risk of neurodegenerative disorders and AD [23:15]; Reducing apoB levels through exercise and diet [31:45]; Pharmacological options for lowering apoB [38:00]; How nutrition impacts longevity via metabolic health, muscle mass, BMD and more [40:15]; How can someone determine the best diet for themselves? [43:45]; Nutrition myth: All weight loss is good [46:45]; Nutrition myth: Metabolic rates are dramatically different among individuals based on genetics [49:00]; Nutrition myth: Losing weight after a brief period of overeating is impossible [53:45]; Nutrition myth: GLP-1 agonists are a replacement for a healthy lifestyle [57:45]; Nutrition myth: There is a single best diet for weight loss [1:03:00]; Nutrition oversimplification: All calories are created equal [1:05:45]; Daily step goals [1:06:45]; The benefits of standing versus sitting throughout the day [1:10:45]; How to identify the most impactful and easiest-to-implement ways to improve your health [1:12:30]; The critical importance of emotional health [1:14:30]; Why supplements should be considered as supportive aids rather than primary solutions in one's strategy to improve longevity [1:18:00]; Strategies for reducing high blood pressure [1:20:45]; Peter's biggest frustrations with "mainstream health advice" [1:28:00]; Peter's chaotic, yet cherished, morning routine [1:31:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

In this Healthed lecture, Prof Andrew Sindone explains that, diet, fluid restriction and exercise are just some of the areas that need addressing when managing heart failure patients according to best practice guidelines. And the importance of these and other non-pharmacological measures should not be underestimated.See omnystudio.com/listener for privacy information.

In this episode, we explore the most effective pharmacologic treatments for fibromyalgia, a complex nociplastic pain syndrome. Dr. Daniel Clauw shares his insights on the top drug classes for managing fibromyalgia and discusses why opioids should be avoided. Could the hyperactive endogenous opioid system in fibromyalgia patients explain the ineffectiveness of opioids? Faculty: Daniel Claw, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Nociplastic Pain Syndromes: Focus on Fibromyalgia Pharmacologic Therapies for Fibromyalgia

Rapha, Ênio e Guilherme Kenzzo conversam sobre Transtorno de Ansiedade Generalizada (TAG): - Quais são os diagnósticos diferenciais? - Como diagnosticar e acompanhar TAG? - Como tratar TAG? Tudo isso nesse episódio! Referências: 1. Szuhany KL, Simon NM. Anxiety Disorders: A Review. JAMA. 2022 Dec 27;328(24):2431-2445. doi: 10.1001/jama.2022.22744. PMID: 36573969. 2. Penninx BW, Pine DS, Holmes EA, Reif A. Anxiety disorders. Lancet. 2021 Mar 6;397(10277):914-927. doi: 10.1016/S0140-6736(21)00359-7. Epub 2021 Feb 11. Erratum in: Lancet. 2021 Mar 6;397(10277):880. PMID: 33581801; PMCID: PMC9248771. 3. Stein MB, Sareen J. CLINICAL PRACTICE. Generalized Anxiety Disorder. N Engl J Med. 2015 Nov 19;373(21):2059-68. doi: 10.1056/NEJMcp1502514. PMID: 26580998. 4. Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press. - Jeremy DeMartini, Gayatri Patel, Tonya L Fancher. Generalized Anxiety Disorder. Ann Intern Med. 2019 Apr 2;170(7):ITC49-ITC64. doi: 10.7326/AITC201904020. 5. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.) 6. Slee, April et al. “Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.” Lancet (London, England) vol. 393,10173 (2019): 768-777. doi:10.1016/S0140-6736(18)31793-8 7. Brawman-Mintzer, Olga et al. “Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.” The Journal of clinical psychiatry vol. 67,6 (2006): 874-81. doi:10.4088/jcp.v67n0603 8. Guaiana, Giuseppe et al. “Hydroxyzine for generalised anxiety disorder.” The Cochrane database of systematic reviews ,12 CD006815. 8 Dec. 2010, doi:10.1002/14651858.CD006815.pub2

This episode of The Metabolic Classroom is sponsored by RxSugar. Use this link to get 20% off: https://rxsugar.com/discount/BEN2002:10 - Overview of Uric Acid: Explanation of what uric acid is and its origins from purine metabolism.03:16 - Uric Acid and Hyperuricemia: Discussion on uric acid production, excretion, and the condition of hyperuricemia.05:09 - Gout and Uric Acid Crystallization: How high uric acid levels lead to gout and kidney stones.07:08 - Importance of Uric Acid in Metabolism: Why uric acid is important, its clinical relevance, and its connection to insulin resistance.09:14 - Uric Acid and Inflammation: How uric acid causes systemic inflammation and contributes to insulin resistance.12:27 - Sources of Uric Acid, Purines and Fructose: Detailed breakdown of purine and fructose metabolism leading to uric acid production.16:31 - Fructose Metabolism and Uric Acid: The role of the liver in metabolizing fructose and its link to uric acid production.22:47 - Pharmacological and Nutritional Interventions: Treatments like allopurinol and the benefits of allulose in reducing uric acid.30:34 - Ketogenic Diet and Uric Acid: The effects of the ketogenic diet on uric acid levels and insulin sensitivity.Summary:In this episode of The Metabolic Classroom, Professor Bikman discusses the significance of uric acid, particularly its impact on insulin resistance. Uric acid, a byproduct of purine metabolism, is usually expelled through the kidneys. When production exceeds excretion, it leads to hyperuricemia, causing gout, kidney stones, and inflammation linked to insulin resistance.Dr. Bikman explains that excessive uric acid activates inflammation pathways, producing ceramides that disrupt insulin signaling, leading to insulin resistance. He highlights the connection between fructose consumption and uric acid production, noting that unregulated fructose metabolism in the liver increases uric acid levels. This rise in fructose intake, rather than purine-rich foods, contributes to gout and metabolic issues.To address this, Dr. Bikman discusses pharmacological interventions like allopurinol, which lowers uric acid levels but may have side effects. He also mentions allulose, a rare sugar that shows promise in reducing uric acid by enhancing its excretion. Despite potentially increasing uric acid, the ketogenic diet is noted for reducing inflammation and improving insulin sensitivity due to ketones.Dr. Bikman concludes by emphasizing the importance of understanding uric acid's role in metabolic health and encourages further research and practical dietary interventions to manage uric acid levels, integrating pharmacological, nutritional, and lifestyle approaches to improve overall metabolic health.Studies referenced in this episode:https://pubmed.ncbi.nlm.nih.gov/24769205/https://www.sciencedirect.com/science/article/abs/pii/S1933171115006063?via=ihub https://www.metabolismjournal.com/article/S0026-0495(65)80039-7/abstract Learn more at: https://www.insuliniq.com Hosted on Acast. See acast.com/privacy for more information.

In this special Complex Care Journal Club podcast episode, co-hosts Kristie Malik, Emily Goodwin and Kathleen Huth interview presenters of posters and oral abstracts relevant to the care of children with medical complexity at the Pediatric Academic Societies (PAS) 2024 annual meeting. Speakers describe the implications of their study findings, messages for patients and families, and priority areas for research that they hope can be investigated further by the complex care community in the coming years. SPEAKERS Mary Arakelyan, MPH Research Project Manager Dartmouth Health Children's Tammie Dewan, MD, MSc Clinical Assistant Professor Department of Pediatrics, University of Calgary Pediatrician, Alberta Children's Hospital Caleb Easterly, BA MD/PhD Student University of North Carolina School of Medicine Kevin Huynh, MS Medical Student University of Pittsburgh School of Medicine Ruchi Kaushik, MD, MEd, MPH Medical Director of Education and Research Imagine Pediatrics, Houston TX Joanna Leyenaar, MD, PhD Professor, Department of Pediatrics Dartmouth Health Children's Savithri Nageswaran, MD, MPH Professor, Department of Pediatrics Wake Forest University School of Medicine Julia Reedy, MA Qualitative Analyst ACCORDS, University of Colorado S. Margaret Wright, MD, MPH Clinical Assistant Professor of Pediatrics University of Missouri-Kansas City School of Medicine Justin Yu, MD, MS Assistant Professor of Pediatrics UPMC Children's Hospital of Pittsburgh HOSTS Kristina Malik, MD Pediatrician, Special Care Clinic, Children's Hospital Colorado Emily J Goodwin, MD Pediatrician, General Academic Pediatrics Beacon Program Children's Mercy Kansas City Kathleen Huth, MD, MMSc Pediatrician, Complex Care Service, Division of General Pediatrics Boston Children's Hospital DATE Initial publication: May 15, 2024. REFERENCES Fehlings D, Agnew B, Gimeno H, Harvey A, Himmelmann K, Lin JP, Mink JW, Monbaliu E, Rice J, Bohn E, Falck-Ytter Y. Pharmacological and neurosurgical management of cerebral palsy and dystonia: Clinical practice guideline update. Dev Med Child Neurol. 2024 Apr 19. doi: 10.1111/dmcn.15921. Epub ahead of print. PMID: 38640091. Pediatric Academic Societies. Who we are. Accessed May 6, 2024. https://www.pas-meeting.org/about/ TRANSCRIPT Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: forms.gle/Bdxb86Sw5qq1uFhW6 Please visit: www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access, thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Malik K, Goodwin EJ, Arakelyan M, Dewan T, Easterly C, Huynh K, Kaushik R, Leyenaar J, Nageswaran S, Reedy J, Wright SM, Yu J, Huth K. Practice-Changing Research in Complex Care at the Pediatric Academic Societies 2024 Annual Meeting. 5/2024. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/practice-changing-research-in-complex-care-at-the-pediatric-academic-societies-2024-annual-meeting

In this Healthed lecture, Professor Andrew Sindone will outline the latest advances in the pharmacological management of heart failure and will present what the evidence now shows to be the most appropriate and effective treatment for this condition to, not only improve symptoms, but also to prolong life.See omnystudio.com/listener for privacy information.

Is your relationship with alcohol affecting your well-being? Listen in as Katie Lain, Founder of Thrive Alcohol Recovery, shares her transformative journey from struggling with alcohol use disorder for nearly 10 years to discovering the Sinclair Method, which completely transformed her relationship with alcohol.  Discover how the Sinclair Method offers a 70-80% success rate in helping individuals regain control over their drinking habits, and learn about the concept of extinction in alcohol addiction treatment.  Join us as we challenge the stigma around alcohol use disorder, the societal pressures to drink, the challenges faced by individuals trying to abstain from alcohol, and explore a revolutionary approach to reclaiming control over your relationship with alcohol.  Also, don't miss out on my FREE E-book, "A Woman's Guide to Estrogen Dominance," providing insights into managing health issues related to estrogen dominance during perimenopause. Download your copy at https://bit.ly/49ZUiWh.   Key Takeaways:  [00:01:35] Drinking and its effects. [00:04:13] Controlling alcohol consumption methods. [00:09:37] Alcohol abuse in older adults. [00:12:00] Overcoming alcoholism with medication. [00:15:32] Alcohol's impact on the body. [00:16:43] Pharmacological extinction through the Sinclair Method. [00:21:20] The Sinclair Method for addiction. [00:23:19] Naltrexone for alcohol use disorder. [00:26:25] Alcohol treatment industry insights. [00:30:29] Alcohol deprivation effect. [00:33:34] Alcohol use disorder stigma. [00:35:33] Slippery slope of increased drinking. [00:39:43] Alcohol-free but not free. [00:42:07] Alcohol addiction development insights. [00:43:34] Addiction and family history. [00:48:49] Alcohol craving and brain rewiring. [00:49:10] Alcohol consumption and breast cancer. Memorable Quotes:  "Not realizing that by repeatedly drinking and also drinking to excess, I was changing my brain and causing this addiction to really set into my brain. And so that's really something that I think is empowering to know that when we have an addiction, it's kind of hijacked our brain. And when we go on the Sinclair Method, it reverses that." – Katie Lain  "My perspective is what doctors don't understand is the craving issue. Because logically, yes, abstinence is probably the safest. And it makes the most sense. It's the easiest to measure. But what I feel like was completely not talked about and ignored in my years of struggle is that mental preoccupation with drinking and the thinking about it." – Katie Lain Links Mentioned: FREE E-Book “A Woman's Guide to Estrogen Dominance”: https://bit.ly/49ZUiWh   Connect with Katie Lain: Website: https://www.thrivealcoholrecovery.com/ Instagram: https://www.instagram.com/embody_daily   Connect with Betty Murray: Living Well Dallas Website: https://www.livingwelldallas.com/ Hormone Reset Website: https://hormonereset.net/ Betty Murray Website: https://www.bettymurray.com/ Facebook: https://www.facebook.com/BettyAMurrayCN/ Instagram: https://www.instagram.com/bettymurray_phd/  

Welcome to our four-episode series: Raising Awareness of Hepatorenal Syndrome Acute Kidney Injury (HRS-AKI). In episode three, our host Muhamad Nadeem Yousaf, MD, speaks with Nikhilesh Mazumder, MD, MPH, Shilpa Junna, MD, and Pratima Sharma, MD, MBBS, MS, to discuss initial management of patients with HRS-AKI. They'll explore topics such as the efficacy of non-selective beta-blockers, the recommended plasma expander for those with decompensated cirrhosis, the roles of renal replacement therapy (RRT), TIPS, and extracorporeal liver support system (ELSS), and the significance of liver transplant in the context of HRS-AKI. Each episode of this series corresponds to a journal article from a September 2023 supplement of Clinical Gastroenterology and Hepatology (CGH), the official clinical practice journal of the American Gastroenterological Association, focusing on addressing knowledge gaps in HRS-AKI. To read the related journal articles and claim CME for listening, visit agau.gastro.org. This series is supported by an independent educational grant from Mallinckrodt

In this episode, Prof. Olivier Rascol provides an overview of his presentation at the MDS-ES Focused Workshop: Diagnostic and Progression Biomarkers in Parkinson's Disease and Atypical Parkinsonism, and discusses his view on ongoing efforts for the development of novel therapeutic strategies for Parkinson's disease and related synucleinopathies.

Im zweiten Teil zum Thema ADHS haben sich Sinja und Boris eine Expertin mit ins Boot geholt. Christiane Altemöller ist ADHS-Coach für Erwachsene und lebt selbst mit der Diagnose ADHS. Sie berichtet von ihren Erfahrungen aus ihrem eigenen Leben und aus ihrem Coaching. Außerdem ergründen die drei, wie ADHS behandelt werden kann und welche Rolle Achtsamkeit dabei spielen kann. Wie gefällt dir Verstehen, fühlen, glücklich sein? Erzähle es uns hier.Hintergründe und Studien:Mehr zu Christiane AltemöllerZur Website Coaching – ADHS ADULT im DIALOGZu Christiane: Linkedin, InstagramCrescenzo, F., Cortese, S., Adamo, N., & Janiri, L. (2016). Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. Evidence-Based Mental Health, 20, 11 - 4. Link zur StudieSonuga-Barke, E., Brandeis, D., Cortese, S., Daley, D., Ferrín, M., Holtmann, M., Stevenson, J., Danckaerts, M., Oord, S., Döpfner, M., Dittmann, R., Simonoff, E., Zuddas, A., Banaschewski, T., Buitelaar, J., Coghill, D., Hollis, C., Konofal, E., Lecendreux, M., Wong, I., & Sergeant, J. (2013). Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments.. The American journal of psychiatry, 170 3, 275-89 . Link zur StudieLambez, B., Harwood-Gross, A., Golumbic, E., & Rassovsky, Y. (2020). Non-pharmacological interventions for cognitive difficulties in ADHD: A systematic review and meta-analysis.. Journal of psychiatric research, 120, 40-55. Link zur StudieXie, Y., Gao, X., Song, Y., Zhu, X., Chen, M., Yang, L., & Ren, Y. (2021). Effectiveness of physical activity intervention on ADHD symptoms: a systematic review and meta-analysis. Frontiers in psychiatry, 12, 706625. Link zur StudieTürk, S., Korfmacher, A. K., Gerger, H., Van der Oord, S., & Christiansen, H. (2023). Interventions for ADHD in childhood and adolescence: A systematic umbrella review and meta-meta-analysis. Clinical Psychology Review, 102271. Link zur StudieChimiklis, A. L., Dahl, V., Spears, A. P., Goss, K., Fogarty, K., & Chacko, A. (2018). Yoga, mindfulness, and meditation interventions for youth with ADHD: Systematic review and meta-analysis. Journal of Child and Family Studies, 27, 3155-3168. Link zur StudieXue, J., Zhang, Y., & Huang, Y. (2019). A meta-analytic investigation of the impact of mindfulness-based interventions on ADHD symptoms. Medicine, 98(23). Link zur StudieOliva, F., Malandrone, F., di Girolamo, G., Mirabella, S., Colombi, N., Carletto, S., & Ostacoli, L. (2021). The efficacy of mindfulness-based interventions in attention-deficit/hyperactivity disorder beyond core symptoms: A systematic review, meta-analysis, and meta-regression. Journal of affective disorders, 292, 475-486. Link zur StudieUnsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

As we all know, rapid and effective resuscitation makes a huge difference to the chance of survival from a cardiac arrest. If you're going to pick a rhythm to have as the patient or as the Resuscitationist, then it's going to be a shockable rhythm, so VF or pulseless VT as they hold the greatest chance of survival. You'll find an initial shockable rhythm in around 20% of cases & defibrillation alone may lead to a ROSC. So it's absolutely imperative to get the immediate management spot on! Whilst current practice is good, there are some aspects of care that we can improve on and make a real difference to outcomes in these patients, with those first on scene or at the bedside in a phenomenally important position to deliver life saving care. In this episode we'll be talking predominantly about refractory VF but the strategy will transfer to how we can also deal with refractory VT cardiac arrests.  We'll be running through all of the following; VF incidence Mechanisms behind VF Refractory and recurrent VF Defibrillation strategies Pharmacological strategies PCI in arrest ECMO Once again we'd love to hear any thoughts or feedback either on the website or via X @TheResusRoom! Simon, Rob & James

Non-pharmacological interventions for the prevention of pain during endotracheal suctioning in ventilated neonates.Pirlotte S, Beeckman K, Ooms I, Cools F.Cochrane Database Syst Rev. 2024 Jan 18;1(1):CD013353. doi: 10.1002/14651858.CD013353.pub2.PMID: 38235838As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

A variety of drugs are used for people with panic disorder and the effects of these were brought together in November 2023 in a Cochrane review and network meta-analysis by Giuseppe Guaiana from Western University in St Thomas Canada and a large group of international authors. Here's Giuseppe to tell us about the problem, and whether these drug treatments are helpful.

A variety of drugs are used for people with panic disorder and the effects of these were brought together in November 2023 in a Cochrane review and network meta-analysis by Giuseppe Guaiana from Western University in St Thomas Canada and a large group of international authors. Here's Giuseppe to tell us about the problem, and whether these drug treatments are helpful.

Episode: BPSD Bootcamp: Practical Guidance to Non-pharmacological Interventions (Part 1 of 2) Host: Diane Sanders-Cepeda, DO, CMD Guest(s): Tana Whitt, MSN, PMHNP-BC; Charissa Duffy, DNP, MSN, APRN, PMHNP-BC; Anthony Nedelman, PhD In This Episode: In this episode, host Diane Sanders-Cepeda, DO, CMD, and special guests Tana Whitt, MSN, PMHNP-MC, Charissa Duffy DNP, MSN, APRN, PMHNP-BC, and Anthony Nedelman, PhD, discuss behavioral and psychological symptoms of dementia (BPSD) to provide listeners with a crash course into nonpharmacological interventions and strategies to support patients with BPSD. Date Recorded: November 9, 2023 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for AMDA On-The-Go and affiliate podcast episodes as follows: Claim CMD Credit

The past half-century: Pharmacological interventions have often fallen short.The potential solution: Microdosing cannabinoids.Imagine a world where you don't reach for a pill bottle.Instead, you opt for:'Go' for energy.'Bliss' for happiness'Chill' for relaxation.The cannabis industry is evolving. Tailored formulations might just be our future, offering specific, targeted effects and reducing reliance on traditional pharmaceuticals.This week, we hosted Peter Barsoom, CEO, and Co-Founder of 1906, to delve into:Why Microdosing Cannabinoids?The intricate science behind creating specific effects formulations.Strain selection to targeted edibles the industry's future.Guest Linkshttps://1906newhighs.com/https://www.instagram.com/1906newhighs/https://twitter.com/1906NewHighsFollow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

The past half-century: Pharmacological interventions have often fallen short.The potential solution: Microdosing cannabinoids.Imagine a world where you don't reach for a pill bottle.Instead, you opt for:'Go' for energy.'Bliss' for happiness'Chill' for relaxation.The cannabis industry is evolving. Tailored formulations might just be our future, offering specific, targeted effects and reducing reliance on traditional pharmaceuticals.This week, we hosted Peter Barsoom, CEO, and Co-Founder of 1906, to delve into:Why Microdosing Cannabinoids?The intricate science behind creating specific effects formulations.Strain selection to targeted edibles the industry's future. Guest Linkshttps://1906newhighs.com/https://www.instagram.com/1906newhighs/https://twitter.com/1906NewHighsFollow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

In this episode, Dr. Arun Mathur, a urologist with specialized knowledge of Parkinson's, explains the symptoms, causes, and treatments of urinary dysfunction in people with Parkinson's. Topics we discuss include: What are the differences between urinary dysfunction in different neurological diseases? What is urinary dysfunction? Urinary dysfunction can be a precursor to a Parkinson's diagnosis How does urinary dysfunction affect a person with Parkinson's quality of life? When should you seek treatment? Urinary dysfunction is more prevalent in Later Onset Parkinson's Non-pharmacological and surgical treatments DBS and Urinary Dysfunction Carbidopa/Levodopa's effect on urinary dysfunction Pharmacological treatments Catheterization Prostate symptoms versus Parkinson's symptoms When will non-pharmacological treatments show results? and more! We hope you enjoy! Want to watch the video recording of this audio? Watch here! To view the show notes and related resources for this webinar, visit our website!

Can an oral medication replace metabolic surgery? Find out about this and more in today's PV Roundup podcast.

Contributor: Aaron Lessen MD Educational Pearls: Patients with alcohol use disorder are frequently discharged from the ED without further resources Pharmacological treatments to reduce cravings in AUD exist Naltrexone  Effective at reducing alcohol cravings and heavy drinking  Gabapentin Reduces the percentage of heavy drinking days in AUD Patients being discharged from the ED should be asked if they feel their alcohol use is a problem, which can further direct appropriate pharmacological interventions References 1. Kranzler M.D. HR, Feinn Ph.D. R, Morris B.A. P, Hartwell Ph.D. EE. A Meta-analysis of the Efficacy of Gabapentin for Treating Alcohol Use Disorder Henry. Addiction. 2019;114(9):1547-1555. doi:10.1111/add.14655 2. Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? Addiction. 2013;108(2):275-293. doi:10.1111/j.1360-0443.2012.04054.x 3. Mariani JJ, Pavlicova M, Basaraba C, et al. Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder. Alcohol Clin Exp Res. 2021;45(8):1639-1652. doi:10.1111/acer.14648 Summarized & Edited by Jorge Chalit, OMSII  

Whether you're in the lab or the field, not feeling like yourself sucks. In this week's episode, both of our storytellers find a way to feel like themselves again. Part 1: Some harsh words from Sarah Kucenas' high school swim coach shake her confidence and she gives up her dream of being a pediatric neurosurgeon. Part 2: When Michael Herrera's COVID turns into long COVID, he struggles to feel like himself until he starts birding. Sarah Kucenas is fascinated by the developing brain. Specifically, she and her research group study how glia act as engineers of neural development. Her long-term goal is to understand the mechanisms that mediate cellular interactions between neurons and glia and use this information to better understand how the human nervous system is initially sculpted, maintained, and behaves during disease. Sarah earned a B.Sc. in Biology from Valparaiso University in 2000 and went on to earn a Ph.D. in Pharmacological & Physiological Science from Saint Louis University with Dr. Mark Voigt in 2005. After Dr. Kucenas' postdoctoral work with Dr. Bruce Appel at Vanderbilt University, she joined the faculty at the University of Virginia in 2009. Sarah has a 11-year-old daughter, Madelyn, 3 (VERY big) dogs, and is a life-long swimmer. Michael Herrera, PhD, is an atmospheric scientist, avid birder, and photographer. His work involves developing and implementing new methods for weather forecasting models, extending forecasts from the surface of earth all the way up to the international space station. He loves spending time outdoors, through birding, kayaking, or helping clean up the local marshes. After a prolonged battle with long COVID, he is rediscovering his curiosity and passion for everything the world has to offer. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Concluding this two-part series on acute respiratory distress syndrome, Sarah and Christian Guzman APRN focus on the treatment options of ARDS and how you can make a difference in the outcome of ARDS patients.They cover the pros and cons of deep sedation, early paralysis, inhaled vasodilators, steroids and more. You'll also learn about the rationale for prone position therapy and ECMO.Topics discussed in this episode:Pharmacological interventions for ARDSPros and Cons to sedation and paralytics for patients with ARDSThe controversial use of steroids and more medicationsBenefits of prone position therapyThe role of fluid managementHow Christian treated his ARDS patientDetermining when to cannulate for ECMO and when take a patient off ECMOChristian's tips on recognizing and treating ARDSIf you would like to check out Sarah's 1hr, 1 CE course, go to: http://www.rapidresponseandrescue.comTo get the FREE Rapid Response RN Assessment Guide and the coupon code for $10 off the cost of the course, message Sarah on Instagram @TheRapidResponseRN and type the word PODCAST!This episode was produced by Podcast Boutique http://www.podcastboutique.comMentioned in this episode:AND If you are planning to sit for your CCRN and would like to take the Critical Care Academy CCRN prep course you can visit https://www.ccrnacademy.com and use coupon code RAPID10 to get 10% off the cost of the course!

Contributor: Aaron Lessen MD Educational Pearls: SCAPE (Sympathetic Crashing Acute Pulmonary Edema), formerly known as flash pulmonary edema, is a life-threatening condition due to a sudden sympathetic surge that leads to hypertensive heart failure, pulmonary edema, hypoxia, and respiratory distress.  The initial treatment for SCAPE stabilization is BiPAP to assist with ventilation. Pharmacological treatment for SCAPE is best achieved with high-dose nitroglycerin (HDN), which induces venodilation and redistributes pulmonary edema. Dosing should be high; boluses of HDN are given at doses of 1-2 mg every 3-5 minutes vs. infusions at 200-400 mcg/min then titrating down. HDN leads to reduced intubations, less need for ICU admission, and shortened length of hospital stay in patients with SCAPE. References Agrawal N, Kumar A, Aggarwal P, Jamshed N. Sympathetic crashing acute pulmonary edema. Indian J Crit Care Med. 2016;20(12):719-723. doi:10.4103/0972-5229.195710 Paone S, Clarkson L, Sin B, Punnapuzha S. Recognition of Sympathetic Crashing Acute Pulmonary Edema (SCAPE) and use of high-dose nitroglycerin infusion. Am J Emerg Med. 2018;36(8):1526.e5-1526.e7. doi:https://doi.org/10.1016/j.ajem.2018.05.013 Stemple K, DeWitt KM, Porter BA, Sheeser M, Blohm E, Bisanzo M. High-dose nitroglycerin infusion for the management of sympathetic crashing acute pulmonary edema (SCAPE): A case series. Am J Emerg Med. 2021;44:262-266. doi:https://doi.org/10.1016/j.ajem.2020.03.062 Wilson SS, Kwiatkowski GM, Millis SR, Purakal JD, Mahajan AP, Levy PD. Use of nitroglycerin by bolus prevents intensive care unit admission in patients with acute hypertensive heart failure. Am J Emerg Med. 2017;35(1):126-131. doi:https://doi.org/10.1016/j.ajem.2016.10.038 Summarized by Jorge Chalit, OMS1 | Edited by Meg Joyce & Jorge Chalit, OMS1

In this episode, Bita Moghaddam discusses the emergence of ketamine as a combat anesthetic in the Vietnam war, its transformation into a recreation drug central to club culture, and its current transition into a treatment for depression.  Ketamine, approved in 2019 by the Food and Drug Administration for the treatment of depression, has been touted by scientists and media reports as something approaching a miracle cure. This volume in the MIT Press Essential Knowledge series chronicles the ascent of a drug that has been around for fifty years--in previous incarnations, a Vietnam-era combat anesthetic and a popular club drug--that has now been reinvented as a treatment for depression. Bita Moghaddam, a leading researcher in neuropharmacology, explains the scientific history and the biology of ketamine, its clinical use, and its recently discovered antidepressant effects, for the nonspecialist reader. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychoanalysis

Sleep, nutrition, and metabolism expert Greg Potter, PhD, is back on the podcast today with a new twist on help for those interested in sleep. Greg is an international public speaker, science writer, consultant and coach, focusing on working with individuals and organisations to adopt easy and long-lasting lifestyle modifications that add years and quality to life. His work has appeared in dozens of worldwide media sources, including Reuters, TIME, and The Washington Post, and he frequently contributes to prominent websites, blogs, and podcasts. On today's podcast, Greg joins Chris to discuss the use of psychedelic drugs for improved sleep and mental health. Greg talks about the types of psychedelics currently being researched, including psilocybin, LSD, and MDMA, their mechanisms of action, and their potential roles in improving sleep and health. He shares some of the most interesting results from the clinical literature, including therapeutic effects for treatment-resistant depression and the impact of these substances when combined with meditation or psychotherapy.  Here's the outline of this episode with Greg Potter: [00:05:28] What are psychedelics? [00:06:33] Main types of psychedelics. [00:09:37] Uses of psychedelics. [00:12:01] Minidosing and microdosing. [00:13:09] Psilocybin use as a spiritually significant event; Study:  Griffiths, Roland R., et al. "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects." Psychopharmacology 218 (2011): 649-665. [00:14:14] Mystical experiences. [00:16:00] Mechanisms of action. [00:20:01] Greg's experience with psychedelics. [00:30:27] Integration work. [00:32:47] Entourage effects. [00:37:18] Chris's experiences with psychedelics. [00:41:22] Relaxing priors; Carhart-Harris and K. Friston; Study: Carhart-Harris, Robin L., and Karl J. Friston. "REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics." Pharmacological reviews 71.3 (2019): 316-344. [00:41:45] Karl Friston's Free Energy Principle; Paper: Friston, Karl. "The free-energy principle: a unified brain theory?." Nature reviews neuroscience 11.2 (2010): 127-138. [00:43:47] Psychedelics and sleep architecture. [00:49:51] Psilocybin and sleep; Study: Dudysová, Daniela, et al. "The effects of daytime psilocybin administration on sleep: implications for antidepressant action." Frontiers in pharmacology 11 (2020): 602590. [00:51:58] Ayahuasca and sleep; Study: Barbanoj, Manel J., et al. "Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers." Psychopharmacology 196 (2008): 315-326. [00:54:34] REM sleep and dreaming. [00:58:42] Hobson's Activation-Synthesis Hypothesis. [00:59:38] Lucid dreaming. [01:00:02] Book: When Brains Dream: Understanding the Science and Mystery of Our Dreaming Minds, by Antonio Zadra and Robert Stickgold. [01:00:04] Videos: TedX talk - Sleep, Memory and Dreams: Fitting the Pieces Together and other videos. [01:03:41] Fear Extinction. [01:05:32] Podcast: From Magic to Mindfulness: The Evolution of an Entrepreneur, with Jason Connell. [01:07:33] Combining LSD and MDMA; Study: Schmid, Yasmin, et al. "Acute subjective effects in LSD-and MDMA-assisted psychotherapy." Journal of Psychopharmacology 35.4 (2021): 362-374. [01:08:31] Psychedelics as adjunct to other interventions. [01:09:16] Review: Payne, Jake E., Richard Chambers, and Paul Liknaitzky. "Combining psychedelic and mindfulness interventions: Synergies to inform clinical practice." ACS Pharmacology & Translational Science 4.2 (2021): 416-423. [01:09:57] Psilocybin combined with other spiritual practices; Study: Griffiths, Roland R., et al. "Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors." Journal of Psychopharmacology 32.1 (2018): 49-69. [01:12:01] Psilocybin with expert meditators; Study: Smigielski, Lukasz, et al. "Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat." Scientific reports 9.1 (2019): 1-13. [01:13:25] Acceptance and Commitment Therapy (ACT). [01:14:59] Podcast: Microdosing Psychedelics and the Placebo Effect, with Balázs Szigeti. [01:20:08] Psilocybin without psychotherapy for treatment-resistant depression; Study: Goodwin, Guy M., et al. "Single-dose psilocybin for a treatment-resistant episode of major depression." New England Journal of Medicine 387.18 (2022): 1637-1648. [01:21:58] Drug harms; Review: Nutt, David J., Leslie A. King, and Lawrence D. Phillips. "Drug harms in the UK: a multicriteria decision analysis." The Lancet 376.9752 (2010): 1558-1565. [01:23:41] Potential contamination; Fentanyl. [01:25:29] Find Greg online: gregpotterphd.com; Instagram.